RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > After String of Quality Issues, J&J CEO Weldon Retires to $143M

After String of Quality Issues, J&J CEO Weldon Retires to $143M

Posted 15 March 2012 | By Alexander Gaffney, RAC 

Outgoing Johnson & Johnson (J&J) Chief Executive Officer William Weldon will receive $143 million in retirement pay, according to a regulatory filing released by J&J.

The company-and Weldon's reputation-were plagued last year by a large number of quality setbacks that caused the US Food and Drug Administration (FDA) to take notice, including a consent decree between FDA and a Pennsylvania manufacturing plant owned by J&J subsidiary McNeil PPC.

Weldon, who has been CEO for ten years and has worked at J&J since 1971, will receive the compensation primarily as the result of deferred and long-term compensation, as well as pension benefits. 

While Weldon won't see these benefits immediately-he assumed the position of Chair of the J&J Board of Directors in April-they still come "at a time when J&J is still fighting the fallout from a series of consumer-drug and device recalls," writes Fierce Pharma.


Read more:

Bloomberg - J&J CEO Weldon to Get $143.5M in Retirement

FiercePharma - J&J's Weldon due for $143M retirement package

Pharmalot - J&J CEO Weldon Gets $143.5M For Retirement

 

© 2022 Regulatory Affairs Professionals Society.